S&P 500   3,963.51 (+0.75%)
DOW   33,749.40 (+0.45%)
QQQ   283.47 (+1.05%)
AAPL   142.51 (+1.11%)
MSFT   246.87 (+1.02%)
META   115.51 (+1.39%)
GOOGL   94.04 (-0.95%)
AMZN   90.41 (+2.20%)
TSLA   173.40 (-0.37%)
NVDA   170.10 (+5.52%)
NIO   13.37 (+6.28%)
BABA   93.91 (+6.32%)
AMD   69.97 (-0.24%)
T   19.09 (-1.09%)
MU   55.15 (+2.47%)
CGC   3.01 (-7.10%)
F   13.13 (+0.23%)
GE   83.43 (-1.85%)
DIS   92.37 (+0.24%)
AMC   6.09 (+0.66%)
PYPL   74.35 (-0.09%)
PFE   51.49 (+2.49%)
NFLX   308.63 (+0.07%)
S&P 500   3,963.51 (+0.75%)
DOW   33,749.40 (+0.45%)
QQQ   283.47 (+1.05%)
AAPL   142.51 (+1.11%)
MSFT   246.87 (+1.02%)
META   115.51 (+1.39%)
GOOGL   94.04 (-0.95%)
AMZN   90.41 (+2.20%)
TSLA   173.40 (-0.37%)
NVDA   170.10 (+5.52%)
NIO   13.37 (+6.28%)
BABA   93.91 (+6.32%)
AMD   69.97 (-0.24%)
T   19.09 (-1.09%)
MU   55.15 (+2.47%)
CGC   3.01 (-7.10%)
F   13.13 (+0.23%)
GE   83.43 (-1.85%)
DIS   92.37 (+0.24%)
AMC   6.09 (+0.66%)
PYPL   74.35 (-0.09%)
PFE   51.49 (+2.49%)
NFLX   308.63 (+0.07%)
S&P 500   3,963.51 (+0.75%)
DOW   33,749.40 (+0.45%)
QQQ   283.47 (+1.05%)
AAPL   142.51 (+1.11%)
MSFT   246.87 (+1.02%)
META   115.51 (+1.39%)
GOOGL   94.04 (-0.95%)
AMZN   90.41 (+2.20%)
TSLA   173.40 (-0.37%)
NVDA   170.10 (+5.52%)
NIO   13.37 (+6.28%)
BABA   93.91 (+6.32%)
AMD   69.97 (-0.24%)
T   19.09 (-1.09%)
MU   55.15 (+2.47%)
CGC   3.01 (-7.10%)
F   13.13 (+0.23%)
GE   83.43 (-1.85%)
DIS   92.37 (+0.24%)
AMC   6.09 (+0.66%)
PYPL   74.35 (-0.09%)
PFE   51.49 (+2.49%)
NFLX   308.63 (+0.07%)
S&P 500   3,963.51 (+0.75%)
DOW   33,749.40 (+0.45%)
QQQ   283.47 (+1.05%)
AAPL   142.51 (+1.11%)
MSFT   246.87 (+1.02%)
META   115.51 (+1.39%)
GOOGL   94.04 (-0.95%)
AMZN   90.41 (+2.20%)
TSLA   173.40 (-0.37%)
NVDA   170.10 (+5.52%)
NIO   13.37 (+6.28%)
BABA   93.91 (+6.32%)
AMD   69.97 (-0.24%)
T   19.09 (-1.09%)
MU   55.15 (+2.47%)
CGC   3.01 (-7.10%)
F   13.13 (+0.23%)
GE   83.43 (-1.85%)
DIS   92.37 (+0.24%)
AMC   6.09 (+0.66%)
PYPL   74.35 (-0.09%)
PFE   51.49 (+2.49%)
NFLX   308.63 (+0.07%)
NASDAQ:TNGX

Tango Therapeutics - TNGX Stock Forecast, Price & News

$7.52
+0.12 (+1.62%)
(As of 12/8/2022 03:10 PM ET)
Add
Compare
Today's Range
$7.38
$7.76
50-Day Range
$3.41
$8.16
52-Week Range
$3.18
$11.73
Volume
2,756 shs
Average Volume
211,482 shs
Market Capitalization
$663.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Tango Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
179.3% Upside
$21.00 Price Target
Short Interest
Bearish
2.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$1.20 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.26) to ($1.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.76 out of 5 stars

Medical Sector

817th out of 1,022 stocks

Pharmaceutical Preparations Industry

401st out of 499 stocks

TNGX stock logo

About Tango Therapeutics (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Receive TNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TNGX Stock News Headlines

Tango Therapeutics Inc (TNGX)
See More Headlines
Receive TNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TNGX Company Calendar

Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNGX
Fax
N/A
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+179.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-58,240,000.00
Net Margins
-418.63%
Pretax Margin
-417.89%

Debt

Sales & Book Value

Annual Sales
$37.04 million
Book Value
$3.94 per share

Miscellaneous

Free Float
84,914,000
Market Cap
$663.11 million
Optionable
Not Optionable
Beta
1.85

Key Executives

  • Dr. Barbara L. Weber M.D. (Age 66)
    Pres, CEO & Director
    Comp: $796.2k
  • Ms. Daniella Beckman CPA (Age 43)
    Chief Financial Officer
    Comp: $545.82k
  • Dr. Alan Huang Ph.D. (Age 49)
    Chief Scientific Officer
    Comp: $566.54k
  • Dr. Alan Ashworth FRS (Age 61)
    Ph.D., Founder & Member of Scientific Advisory Board
  • Dr. Levi Garraway M.D.
    Ph.D., Founder
  • Dr. William G. Kaelin Jr. (Age 64)
    M.D., Founder & Member of Scientific Advisory Board
  • Dr. Timothy K. Lu M.D. (Age 41)
    Ph.D., Founder
  • Dr. Antoni Ribas M.D. (Age 55)
    Ph.D., Founder & Member of Scientific Advisory Board
  • Mr. Douglas J. Barry Esq. (Age 52)
    J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Mr. John C. Ross M.S.
    VP of HR













TNGX Stock - Frequently Asked Questions

Should I buy or sell Tango Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNGX shares.
View TNGX analyst ratings
or view top-rated stocks.

What is Tango Therapeutics' stock price forecast for 2023?

1 analysts have issued 12 month price objectives for Tango Therapeutics' shares. Their TNGX share price forecasts range from $21.00 to $21.00. On average, they expect the company's share price to reach $21.00 in the next year. This suggests a possible upside of 179.3% from the stock's current price.
View analysts price targets for TNGX
or view top-rated stocks among Wall Street analysts.

How have TNGX shares performed in 2022?

Tango Therapeutics' stock was trading at $10.94 at the beginning of 2022. Since then, TNGX stock has decreased by 31.3% and is now trading at $7.52.
View the best growth stocks for 2022 here
.

When is Tango Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our TNGX earnings forecast
.

What is Tango Therapeutics' stock symbol?

Tango Therapeutics trades on the NASDAQ under the ticker symbol "TNGX."

Who are Tango Therapeutics' major shareholders?

Tango Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include EcoR1 Capital LLC (4.76%), Cormorant Asset Management LP (4.68%), BlackRock Inc. (3.31%), Vanguard Group Inc. (2.95%), State Street Corp (0.99%) and Citadel Advisors LLC (0.54%).
View institutional ownership trends
.

How do I buy shares of Tango Therapeutics?

Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tango Therapeutics' stock price today?

One share of TNGX stock can currently be purchased for approximately $7.52.

How much money does Tango Therapeutics make?

Tango Therapeutics (NASDAQ:TNGX) has a market capitalization of $663.11 million and generates $37.04 million in revenue each year. The company earns $-58,240,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

How can I contact Tango Therapeutics?

Tango Therapeutics' mailing address is 12860 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.tangotx.com. The company can be reached via phone at 857-320-4900.

This page (NASDAQ:TNGX) was last updated on 12/8/2022 by MarketBeat.com Staff